|
Jun 8
|
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
Jun 8
|
Can This Gene-Editing Stock Deliver 10X Returns?
|
|
Jun 8
|
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
|
|
Jun 7
|
Why Is CRISPR Therapeutics AG (CRSP) Up 1.8% Since Last Earnings Report?
|
|
Jun 6
|
3 Top Healthcare Stocks to Buy for June
|
|
May 13
|
Is CRISPR Therapeutics Stock a Buy Now?
|
|
May 11
|
Why These 3 Nasdaq Stocks Were Glowing Green This Week
|
|
May 10
|
CRISPR Therapeutics Stock Sees Relative Strength Rating Rise To 89
|
|
May 10
|
CRISPR Therapeutics First Quarter 2023 Earnings: Beats Expectations
|
|
May 9
|
Why CRISPR Therapeutics Stock Is on Fire Today
|
|
May 9
|
CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat
|
|
May 8
|
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 8
|
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
|